Luc F. Van Gaal
#158,386
Most Influential Person Now
Luc F. Van Gaal's AcademicInfluence.com Rankings
Luc F. Van Gaalphilosophy Degrees
Philosophy
#9034
World Rank
#12527
Historical Rank
Logic
#6036
World Rank
#7513
Historical Rank

Download Badge
Philosophy
Luc F. Van Gaal's Degrees
- PhD Medicine University of Amsterdam
- Doctorate Medicine University of Amsterdam
Why Is Luc F. Van Gaal Influential?
(Suggest an Edit or Addition)Luc F. Van Gaal's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. (2010) (839)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. (2021) (630)
- Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes (2005) (549)
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide (2011) (549)
- Human leptin: from an adipocyte hormone to an endocrine mediator. (2000) (479)
- TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) (468)
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) (426)
- Body surface area in normal-weight, overweight, and obese adults. A comparison study. (2006) (387)
- The beneficial effects of modest weight loss on cardiovascular risk factors. (1997) (313)
- Overweight, obesity, and blood pressure: the effects of modest weight reduction. (2000) (308)
- The Effect of Exercise on Visceral Adipose Tissue in Overweight Adults: A Systematic Review and Meta-Analysis (2013) (285)
- Sleep-disordered breathing in overweight and obese children and adolescents: prevalence, characteristics and the role of fat distribution (2006) (245)
- PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. (2015) (226)
- Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. (2015) (223)
- The prevalence, anatomical correlates and treatment of sleep-disordered breathing in obese children and adolescents. (2008) (193)
- Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. (2009) (175)
- Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum (2015) (167)
- Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. (2014) (162)
- Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment (2015) (160)
- Progress and challenges in anti-obesity pharmacotherapy. (2017) (159)
- Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. (2018) (159)
- Variants in the FTO gene are associated with common obesity in the Belgian population. (2008) (157)
- Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients (2008) (156)
- Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. (2008) (147)
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. (2014) (145)
- Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. (2011) (144)
- Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults (2013) (142)
- Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial (2012) (140)
- Sleep-disordered breathing and the metabolic syndrome in overweight and obese children and adolescents. (2007) (138)
- Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. (2007) (135)
- Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study (1998) (135)
- Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2014) (134)
- Reference values for sleep‐related respiratory variables in asymptomatic European children and adolescents (2007) (130)
- Transcriptional Activation of Apolipoprotein CIII Expression by Glucose May Contribute to Diabetic Dyslipidemia (2011) (128)
- Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? (2014) (125)
- Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids (2013) (123)
- Autoimmune gastritis in type 1 diabetes: a clinically oriented review. (2008) (115)
- Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. (2009) (114)
- Effect of Long-Term Whole Body Vibration Training on Visceral Adipose Tissue: A Preliminary Report (2010) (111)
- Prevalence of Loss-of-Function FTO Mutations in Lean and Obese Individuals (2009) (110)
- High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry. (2000) (109)
- Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. (2016) (106)
- Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. (2012) (105)
- Addition of rosiglitazone to metformin is most effective in obese, insulin‐resistant patients with type 2 diabetes (2003) (104)
- Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel (2005) (103)
- Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. (2006) (101)
- Heterozygous Mutations Causing Partial Prohormone Convertase 1 Deficiency Contribute to Human Obesity (2012) (99)
- Loss-of-function mutations in SIM1 contribute to obesity and Prader-Willi-like features. (2013) (99)
- Leptin receptor gene polymorphisms are associated with insulin in obese women with impaired glucose tolerance. (2001) (98)
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity (2019) (97)
- Leptin levels in type 2 diabetes: associations with measures of insulin resistance and insulin secretion. (2003) (97)
- C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. (2011) (95)
- Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases (1999) (92)
- Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks (2012) (88)
- Belgian consensus on metabolic problems associated with atypical antipsychotics (2005) (86)
- Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). (2003) (84)
- Impact of overweight on chronic microvascular complications in type 1 diabetic patients. (2005) (83)
- Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. (2003) (82)
- Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. (2012) (80)
- Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin. (2017) (80)
- Contribution of Antibodies Against IA-2β and Zinc Transporter 8 to Classification of Diabetes Diagnosed Under 40 Years of Age (2011) (79)
- Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution (2019) (78)
- Association of the BDNF Val66Met variation with obesity in women. (2008) (78)
- Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results (2008) (75)
- Sleep-disordered breathing, obesity, and airway inflammation in children and adolescents. (2008) (74)
- Impact of diabetes mellitus on the relationships between iron‐, inflammatory‐ and oxidative stress status (2006) (74)
- Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. (2007) (73)
- Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients (2002) (72)
- Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. (2009) (71)
- Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects (2017) (71)
- A rapid and simple method for measuring the susceptibility of low-density-lipoprotein and very-low-density-lipoprotein to copper-catalyzed oxidation. (1994) (71)
- Daily intake of bisphenol A and triclosan and their association with anthropometric data, thyroid hormones and weight loss in overweight and obese individuals. (2015) (67)
- The in vitro oxidizability of lipoprotein particles in obese and non-obese subjects. (1998) (67)
- Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. (2001) (65)
- Intensive Insulin Therapy in the Intensive Care Unit (2006) (64)
- Phthalate metabolites in obese individuals undergoing weight loss: Urinary levels and estimation of the phthalates daily intake. (2013) (63)
- Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals (2013) (62)
- Considerable exposure to the endocrine disrupting chemicals phthalates and bisphenol-A in intensive care unit (ICU) patients. (2015) (61)
- Exposure to Persistent Organic Pollutants: Relationship With Abnormal Glucose Metabolism and Visceral Adiposity (2014) (60)
- Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis (2010) (60)
- Visceral fat as a determinant of fibrinolysis and hemostasis. (2005) (60)
- Human obesity: from lipid abnormalities to lipid oxidation. (1995) (59)
- Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD (2016) (59)
- X‐PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced‐energy diet. Early response to treatment predicts weight maintenance (2005) (58)
- Sleep-disordered breathing and uric acid in overweight and obese children and adolescents. (2007) (57)
- Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. (2000) (55)
- Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. (1996) (54)
- Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? (2008) (54)
- Leptin levels, leptin receptor gene polymorphisms, and energy metabolism in women. (2002) (54)
- Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features (2015) (53)
- Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. (2004) (51)
- Delayed gastric emptying and gastric autoimmunity in type 1 diabetes. (2002) (49)
- Screening for therapeutic trials and treatment indication in clinical practice: MACK‐3, a new blood test for the diagnosis of fibrotic NASH (2018) (47)
- Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: a double blind, placebo controlled randomized trial (2015) (47)
- The role of the leptin-melanocortin signalling pathway in the control of food intake. (2009) (46)
- Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? (1998) (46)
- A Review of Current Evidence with Continuous Glucose Monitoring in Patients with Diabetes (2008) (45)
- LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial (2016) (45)
- Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial (2014) (45)
- High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. (1999) (44)
- Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. (1995) (43)
- Gastric parietal cell antibodies are associated with glutamic acid decarboxylase‐65 antibodies and the HLA DQA1*0501‐DQB1*0301 haplotype in Type 1 diabetes mellitus (2000) (43)
- Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. (2011) (42)
- Dynamics of organohalogenated contaminants in human serum from obese individuals during one year of weight loss treatment. (2013) (42)
- Current concepts in gastric motility in diabetes mellitus. (2006) (42)
- Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity. (2021) (42)
- Long term magnesium supplementation influences favourably the natural evolution of neuropathy in Mg-depleted type 1 diabetic patients (T1dm). (2004) (41)
- Miglitol combined with metformin improves glycaemic control in type 2 diabetes (2001) (41)
- Association study of MC4R with complex obesity and replication of the rs17782313 association signal. (2011) (41)
- Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. (1998) (40)
- Intensive insulin therapy in the intensive care unit: assessment by continuous glucose monitoring (2005) (40)
- Phenotypic expression and frequency of familial defective apolipoprotein B-100 in Belgian hypercholesterolemics. (1994) (40)
- Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation. (2005) (40)
- Expression of Obesity Markers and Persistent Organic Pollutants Levels in Adipose Tissue of Obese Patients: Reinforcing the Obesogen Hypothesis? (2014) (39)
- Apolipoprotein concentrations in obese subjects with upper and lower body fat mass distribution. (1989) (39)
- Urinary phthalate metabolites are associated with insulin resistance in obese subjects. (2015) (38)
- Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. (1996) (38)
- Insulin Resistance and Environmental Pollutants: Experimental Evidence and Future Perspectives (2013) (37)
- Sarcopenia in patients with non‐alcoholic fatty liver disease: is it a clinically significant entity? (2018) (36)
- Pharmacological Approaches in the Treatment and Maintenance of Weight Loss (2016) (35)
- Upper body adiposity and the risk for atherosclerosis. (1989) (35)
- Hemoperfusion-hemodialysis ineffective for paraquat removal in life-threatening poisoning? (1985) (35)
- SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus (2014) (34)
- Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders. (2005) (33)
- Glucose control and use of continuous glucose monitoring in the intensive care unit: a critical review. (2008) (33)
- Helicobacter pylori, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus (2002) (33)
- Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. (2009) (33)
- Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes (2017) (33)
- Blood pressure changes associated with sibutramine and weight management – an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes trial (SCOUT) * (2009) (32)
- Gender differences in leptin levels and physiology: a role for leptin in human reproduction. (1999) (31)
- Identification of Three Novel Genetic Variants in the Melanocortin‐3 Receptor of Obese Children (2011) (31)
- Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα (2019) (31)
- Coenzyme Q as an antiadipogenic factor. (2011) (30)
- Blood viscosity in human obesity: relation to glucose tolerance and insulin status. (1989) (30)
- Autoimmune hepatitis, autoimmune gastritis, and gastric carcinoid in a type 1 diabetic patient: a case report. (2000) (29)
- Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes (2013) (28)
- The role of nocturnal pulse oximetry in the screening for obstructive sleep apnea in obese children and adolescents. (2015) (28)
- [Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics]. (2005) (28)
- Early endothelial dysfunction in young type 1 diabetics. (2009) (28)
- Minimally-invasive and non-invasive continuous glucose monitoring systems: indications, advantages, limitations and clinical aspects. (2008) (28)
- Pivotal Role for the Visceral Fat Compartment in the Release of Persistent Organic Pollutants During Weight Loss. (2015) (27)
- Plasma BCAA changes in Patients with NAFLD are Sex Dependent. (2020) (26)
- Predicting type 2 diabetes mellitus: a comparison between the FINDRISC score and the metabolic syndrome (2018) (26)
- Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. (2004) (26)
- Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects (2017) (25)
- Hemostasis and fibrinolysis in non-diabetic overweight and obese men and women. Is there still a role for leptin? (2006) (25)
- The age at diagnosis of type 1 diabetes continues to decrease in Belgian boys but not in girls: a 15‐year survey (2007) (25)
- Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus (2012) (25)
- Sleep duration and metabolic dysregulation in overweight children and adolescents (2007) (25)
- Factors determining energy expenditure during very-low-calorie diets. (1992) (24)
- CNV analysis and mutation screening indicate an important role for the NPY4R gene in human obesity (2016) (24)
- Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin. (2004) (24)
- Screening for type 2 diabetes mellitus in overweight and obese subjects made easy by the FINDRISC score. (2016) (23)
- Copy number variation (CNV) analysis and mutation analysis of the 6q14.1-6q16.3 genes SIM1 and MRAP2 in Prader Willi like patients. (2016) (23)
- Rationale and options for combination therapy in the treatment of Type 2 diabetes (2003) (23)
- Fluoxetine therapy in obese diabetic and glucose intolerant patients. (1992) (23)
- Metabolic syndrome in youth: a cross‐sectional school‐based survey (2007) (23)
- Dose-response of simvastatin in primary hypercholesterolemia. (1994) (22)
- Do E‐cigarettes induce weight changes and increase cardiometabolic risk? A signal for the future (2017) (22)
- Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus☆ (2014) (22)
- Associations of leptin with body fat distribution and metabolic parameters in non-insulin-dependent diabetic patients: no effect of apolipoprotein E polymorphism. (2000) (22)
- Are all glitazones the same? (2002) (21)
- Assessment of body composition by skinfold anthropometry and bioelectrical impedance technique: a comparative study. (1994) (21)
- Sleep-disordered breathing, systemic adipokine secretion, and metabolic dysregulation in overweight and obese children and adolescents. (2017) (21)
- Magnesium and obesity: influence of gender, glucose tolerance, and body fat distribution on circulating magnesium concentrations. (1992) (21)
- Identification of mutations in the NUCB2/nesfatin gene in children with severe obesity. (2012) (20)
- Anthropometric and calorimetric evidence for the protein sparing effects of a new protein supplemented low calorie preparation. (1985) (20)
- Overweight in adolescents: differences per type of education. Does one size fit all? (2008) (20)
- New International Diabetes Federation (IDF) and National Cholesterol Education Program Adult Treatment panel III (NCEP‐ATPIII) criteria and the involvement of hemostasis and fibrinolysis in the metabolic syndrome (2006) (20)
- Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. (2010) (20)
- Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. (2018) (20)
- Weight and blood pressure response to weight management and sibutramine in diabetic and non‐diabetic high‐risk patients: an analysis from the 6‐week lead‐in period of the sibutramine cardiovascular outcomes (SCOUT) trial (2010) (20)
- The Effect of Lifestyle Interventions on Excess Ectopic Fat Deposition Measured by Noninvasive Techniques in Overweight and Obese Adults: A Systematic Review and Meta-Analysis. (2016) (20)
- Identification and Functional Characterization of Novel Mutations in the Melanocortin-4 Receptor (2010) (20)
- Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. (2001) (19)
- A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial (2017) (19)
- Sleep-disordered breathing and pulmonary function in obese children and adolescents. (2014) (19)
- Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women? (2006) (19)
- A comparison of two insulin infusion protocols in the medical intensive care unit by continuous glucose monitoring (2016) (19)
- Plasma adiponectin level is inversely correlated with albuminuria in overweight and obese nondiabetic individuals. (2013) (19)
- Postprandial glucose monitoring in type 1 diabetes mellitus: use of a continuous subcutaneous monitoring device (2004) (19)
- LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial (2016) (18)
- The safety of obesity drugs – correspondence (2007) (17)
- New approaches for the management of patients with multiple cardiometabolic risk factors. (2006) (17)
- Importance of glucagon as a determinant of resting metabolic rate and glucose-induced thermogenesis in obese women. (1991) (17)
- Sleep-disordered breathing and systemic inflammation in overweight children and adolescents. (2008) (16)
- Sex hormones, body fat distribution, resting metabolic rate and glucose-induced thermogenesis in premenopausal obese women. (1994) (16)
- A case of malnutrition after biliopancreatic diversion for morbid obesity. (1993) (16)
- Sleep disordered breathing and autonomic function in overweight and obese children and adolescents (2016) (16)
- Monogenic and complex forms of obesity: insights from genetics reveal the leptin-melanocortin signaling pathway as a common player. (2012) (16)
- Weight reduction with a high protein, low carbohydrate, calorie-restricted diet: effects on blood pressure, glucose and insulin levels. (1989) (16)
- Endocrine-disrupting polychlorinated biphenyls in metabolically healthy and unhealthy obese subjects before and after weight loss: difference at the start but not at the finish. (2016) (16)
- Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. (1995) (16)
- Prevalence of rare MC3R variants in obese cases and lean controls (2013) (15)
- The effect of diet or exercise on ectopic adiposity in children and adolescents with obesity: a systematic review and meta‐analysis (2017) (15)
- Time Course of Oxidative Stress Status in the Postprandial and Postabsorptive States in Type 1 Diabetes Mellitus: Relationship to Glucose and Lipid Changes (2005) (15)
- Short and long term effects of a very low calorie diet on resting metabolic rate and body composition. (1989) (15)
- Misdiagnosis of Graves’ hyperthyroidism due to therapeutic biotin intervention (2017) (15)
- Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity. (2006) (15)
- Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood. (2002) (15)
- Modern, new pharmacotherapy for obesity. A gastrointestinal approach. (2004) (14)
- Association Study and Mutation Analysis of Adiponectin Shows Association of Variants in APM1 with Complex Obesity in Women (2009) (14)
- Decreased diet-induced thermogenesis in gluteal-femoral obesity. (1989) (14)
- Replication of the SH2B1 rs7498665 Association with Obesity in a Belgian Study Population (2011) (14)
- Dynamics of persistent organic pollutants in obese adolescents during weight loss. (2018) (14)
- NASH-related increases in plasma bile acid levels depend on insulin resistance (2020) (14)
- Glucose Intolerance and the Amount of Visceral Adipose Tissue Contribute to an Increase in Circulating Triglyceride Concentrations in Caucasian Obese Females (2012) (13)
- Health risks of lipodystrophy and abdominal fat accumulation: therapeutic possibilities with leptin and human growth hormone. (2003) (12)
- Obesity in Europe – does anybody care? (2013) (12)
- Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. (1991) (12)
- Role of hepatic arterial embolisation in the treatment for metastatic insulinoma. Report of two cases and review of the literature. (1997) (12)
- Decreased hepatic insulin extraction in upper body obesity: relationship to unbound androgens and sex hormone binding globulin. (1991) (12)
- Accurate non‐invasive diagnosis and staging of non‐alcoholic fatty liver disease using the urinary steroid metabolome (2020) (12)
- Low-density lipoprotein receptor gene mutation analysis and clinical correlation in Belgian hypercholesterolaemics. (2001) (11)
- GLP-1 receptor agonists for type 2 diabetes. (2009) (11)
- Screening for genetic variants in BDNF that contribute to childhood obesity (2014) (11)
- A Preliminary Link between Hydroxylated Metabolites of Polychlorinated Biphenyls and Free Thyroxin in Humans (2016) (11)
- Genetic association between WNT10B polymorphisms and obesity in a Belgian case-control population is restricted to males. (2012) (11)
- Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program (2019) (11)
- Clinical Predictors of Residual Sleep Apnea after Weight Loss Therapy in Obese Adolescents (2018) (11)
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (2012) (10)
- Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function—Mechanisms and Possible Therapeutic or Preventive Measures: an Update (2021) (10)
- The metabolic syndrome and the liver. (2008) (10)
- Identification of prediabetes in first‐degree relatives at intermediate risk of type I diabetes (2007) (10)
- Common melanocortin-3 receptor variants are not associated with obesity, although rs3746619 does influence weight in obese individuals (2010) (10)
- Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates (2008) (10)
- Evaluation of magnesium before and after jejuno-ileal versus gastric bypass surgery for morbid obesity. (1987) (9)
- Sleep-Disordered Breathing and Proteinuria in Overweight and Obese Children and Adolescents (2008) (9)
- Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial (2017) (9)
- Hypertension in obese and non-obese non-insulin dependent diabetics a matter of regional adiposity? (1988) (8)
- Plasma zinc levels in diabetes mellitus: relation to plasma albumin and amino acids. (1986) (8)
- Genetic and structural variation in the SH2B1 gene in the Belgian population. (2015) (8)
- Opposite effects of insulin-like molecules and leptin in coronary heart disease of type 2 diabetes Preliminary data. (2006) (8)
- Evaluation of a Role for NPY and NPY2R in the Pathogenesis of Obesity by Mutation and Copy Number Variation Analysis in Obese Children and Adolescents (2018) (8)
- Common genetic variation in sFRP5 is associated with fat distribution in men (2014) (8)
- Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives (2007) (8)
- Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials. (2017) (8)
- Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes (2016) (8)
- Prolyl carboxypeptidase activity in the circulation and its correlation with body weight and adipose tissue in lean and obese subjects (2018) (7)
- Incidence and predisposing factors for the development of disturbed glucose metabolism and DIabetes mellitus AFter Intensive Care admission: the DIAFIC study (2015) (7)
- Effect of a long term very low calorie diet on glucose/insulin metabolism in obesity. Influence of fat distribution on hepatic insulin extraction. (1989) (7)
- Magnesium and obesity: effects of treatment on magnesium and other parameters. (1987) (7)
- Prolonged flare-up of testosterone after administration of a gonadotrophin agonist to a sex offender: an under-recognised risk? (2015) (7)
- Impact of obesity on resting metabolic rate and glucose-induced thermogenesis in non-insulin dependent diabetes mellitus. (1992) (7)
- Lipid and lipoprotein changes after long-term weight reduction: the influence of gender and body fat distribution. (1995) (7)
- Bariatric surgery to treat type 2 diabetes: what is the recent evidence? (2012) (7)
- PAI‐1 activity, but not fibrinogen or von Willebrand factor, is inversely related to LDL particle size in type 2 diabetes (2008) (7)
- Fainting and hemolysis during blood sampling in youngsters: prevalence study. (2008) (6)
- Blood rheology during an intensified conventional insulin treatment (ICIT) in insulin-dependent diabetes. (1989) (6)
- Coronary artery calcifications and diastolic dysfunction versus visceral fat area in type 1 diabetes: VISCERA study. (2017) (6)
- Abnormal longitudinal peak systolic strain in asymptomatic patients with type I diabetes mellitus (2019) (6)
- Diabetic keto-acidosis as a presentation of cystic fibrosis-related diabetes: a case report. (2011) (6)
- Changes in vitamin E status during obesity treatment. (1987) (6)
- Operations for failed vertical banded gastroplasty. (1994) (6)
- Efficacy and safety of high-dose GLP-1, GLP-1/GIP and GLP-1/glucagon receptor agonists in type 2 diabetes. (2022) (6)
- Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial (2014) (6)
- Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study). (2016) (6)
- Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. (2016) (5)
- A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease (2021) (5)
- NAFLD in type 1 diabetes: overrated or underappreciated? (2021) (5)
- [Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes]. (2010) (5)
- Randomized Evaluation of Glycemic Control in the Medical Intensive Care Unit Using Real-Time Continuous Glucose Monitoring (REGIMEN Trial). (2015) (5)
- Response to Comment on Home et al. Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? Diabetes Care 2014;37:1499–1508 (2014) (5)
- Cardiometabolic importance of 1-h plasma glucose in obese subjects (2019) (5)
- Hyperkalemia in Diabetic Ketoacidosis (1981) (4)
- Adenotonsillectomy as first-line treatment for sleep-disordered breathing in obese children. (2008) (4)
- [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. (2007) (4)
- The Cushing Reflex: Oliguria as a Reflection of an Elevated Intracranial Pressure (2017) (4)
- Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease (2020) (4)
- Copy number variant analysis and expression profiling of the olfactory receptor-rich 11q11 region in obesity predisposition (2020) (4)
- [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]. (2008) (4)
- Posttranscriptional Regulation of the Human LDL Receptor by the U2-Spliceosome (2021) (3)
- Repeated measurements of bioelectrical impedance. (1994) (3)
- Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials (2019) (3)
- Therapeutic approaches for non-alcoholic steatohepatitis (2021) (3)
- Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study (2019) (3)
- Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. (2016) (3)
- Investigation of common and rare genetic variation in the BAMBI genomic region in light of human obesity (2016) (3)
- Effects of micronized fenofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus. (2005) (3)
- Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study (2021) (3)
- [The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]. (2005) (3)
- [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]. (2010) (3)
- Health-related costs in a sample of premenopausal non-diabetic overweight or obese females in Antwerp region: a cost-of-illness analysis (2018) (3)
- Identification and functional characterization of a missense mutation in resistin in two patients with severe obesity and insulin resistance. (2011) (3)
- Author Correction: Transcriptional network analysis implicates altered hepatic immune function in NASH development and resolution (2019) (3)
- Effects of smoking on lipid parameters during therapeutic weight loss. (1986) (3)
- Hypothyroidism and prolactin. (1981) (2)
- Obesity, health issues, and cardiovascular disease. (2005) (2)
- Intronic mutations at splice junctions in the low-density lipoprotein receptor gene. (1999) (2)
- [Effects of the relative enrichment of polyunsaturated fatty acids in insulin-dependent diabetic patients]. (1986) (2)
- Tackling obesity during the COVID‐19 pandemic (2020) (2)
- Evolution of Serum α‐Tocopherol in the Postprandial and Postabsorptive Phases in Type 1 Diabetes Mellitus (2004) (2)
- No conclusive evidence for association of polymorphisms in the adiponectin receptor 1 gene, AdipoR1, with common obesity (2013) (2)
- Nucleotide variation of sFRP5 gene is not associated with obesity in children and adolescents (2016) (2)
- [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]. (2012) (2)
- [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. (2010) (2)
- [Medication of the month... Exenatide (Byetta) incretinomimetic in the treatment of type 2 diabetes after failure and as add-on therapy to oral agents]. (2008) (2)
- Vaping and Cardiovascular Health: the Case for Health Policy Action (2019) (2)
- 22nd European Congress on Obesity (ECO2015), Prague, Czech Republic, May 6-9, 2015: Abstracts (2015) (2)
- [Endocannabinoid system in the brain...and elsewhere]. (2008) (2)
- [Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study]. (2009) (2)
- Features of oral glucose tolerance tests in patients after Roux‐en‐Y gastric bypass with and without hypoglycaemia symptoms in daily life: It's all about speed (2020) (2)
- Vitamin E status in gold-thioglucose-treated obese mice: the influence of weight loss. (1985) (2)
- Reducing cardiometabolic risk through selective antagonism of CB1 receptors. (2007) (1)
- Sleep duration and insulin resistance in obese children: when variables are sleeping too close together. (2007) (1)
- Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese women (2005) (1)
- Assessing the impact of complications on the costs of Type II diabetes. (2002) (1)
- Can Bariatric Surgery be Considered Standard Therapy to Treat Type 2 Diabetes? (2013) (1)
- Efficacy and safety of exenatide once weekly: an overview of the DURATION trials (2012) (1)
- European Obesity Summit (EOS) – Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1 – 4, 2016: Abstracts (2016) (1)
- Cushing's syndrome, due to ectopic ACTH-secretion, successfully treated with aminoglutethimide, radiotherapy and chemotherapy. (1981) (1)
- European Obesity Summit (EOS) – Joint Congress of EASO and IFSO-EC, Gothenburg, Sweden, June 1 – 4, 2016: Abstracts (2016) (1)
- [Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]. (2005) (1)
- Another Prolactin-secreting Pituitary Tumor in an Insulindependent Diabetic Patient (1984) (1)
- Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction. (1989) (1)
- Insulin lispro (Humalog) in the treatment of diabetes mellitus: overview of belgian clinical data from global studies. (1999) (1)
- Reverse T3 changes during protein supplemented diets. Relation to nutrient combustion rates. (1989) (1)
- Endocrine abnormalities related to total and regional fat mass accumulation. (1992) (1)
- A lesson from IVF endocrinology: the importance of the follicular phase to success and failure in non-IVF cycles. (1986) (1)
- DNA sequencing and copy number variation analysis of MCHR2 in a cohort of Prader Willi like (PWL) patients. (2017) (1)
- No important role for genetic variation in the Chibby gene in monogenic and complex obesity (2013) (1)
- [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system]. (2008) (1)
- An Intact Dopamine Sensitivity in the Brain: A Necessity to Recover Hyperprolactinemia and Galactorrhea in a Female Hemodialysis Patient? (2017) (1)
- [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]. (2013) (1)
- Can calculated total nitrogen replace Kjeldahl total nitrogen measurements in 24-h urine samples? (2018) (0)
- A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease (2021) (0)
- Influence of mebendazole administration on metabolic control in type 1 (insulin-dependent) diabetic patients. (1985) (0)
- The "endocrine" dysmetabolism of visceral obesity. Lessons from exercise research. (1993) (0)
- Pharmacologic Treatment of Obesity (2012) (0)
- Insulinotropic effect of different formula of very low calorie protein supplemented diets in obesity. (1987) (0)
- Myosteatosis is associated with early NASH in the context of obesity and metabolic syndrome (2020) (0)
- Evolution of serum alpha-tocopherol in the postprandial and postabsorptive phases in type 1 diabetes mellitus. (2004) (0)
- Glucagon and hyperkalaemia in decompensated diabetes. (1982) (0)
- Upper body fat predominance: an endocrine and metabolic chaos. (1991) (0)
- [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes]. (2008) (0)
- [Course and treatment of diabetic nephropathy]. (1986) (0)
- Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes (2022) (0)
- New pharmacological directions for the treatment of overweight and obesity. (1999) (0)
- Insulin antibodies before and 1 year after the change-over from U40 to U100 insulin preparations in Belgium. (1994) (0)
- Human obesity: a medical assessment of health risks. (1995) (0)
- 751-P: Effect Of Once-Weekly Semaglutide on Weight Change and Metabolic Control in People with Type 1 Diabetes—Six-Months Results from the Real-World STEMT Trial (2022) (0)
- Body fat, body fat distribution and the respiratory system: a "fat neck" syndrome? (1992) (0)
- [Value of the aminogram in the diabetic picture]. (1986) (0)
- [In Process Citation] (2000) (0)
- Nucleotide variation of sFRP5 gene is not associated with obesity in children and adolescents (2016) (0)
- [Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study "SUGAR"]. (2011) (0)
- [Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes]. (2013) (0)
- Long-term efficacy of semi-synthetic human insulins (SHI) in newly-diagnosed insulin-dependent diabetic patients. A two year clinical study. (1986) (0)
- No important role for genetic variation in the Chibby gene in monogenic and complex obesity (2013) (0)
- Metabolic syndrome--from controversies to ectopic fat syndrome. (2010) (0)
- Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1) (2021) (0)
- [Transition from insulin U-40 to insulin U-100: the Belgian experience]. (1992) (0)
- [Place of fibrates for the treatment of patients with atherogenic dyslipidemia]. (2009) (0)
- [Risk factors for atherosclerosis in non-insulin-dependent diabetes]. (1992) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Luc F. Van Gaal?
Luc F. Van Gaal is affiliated with the following schools: